Immunosuppressive therapeutic effects of G2013 in experimental model of multiple sclerosis

Background: Experimental autoimmune encephalomyelitis (EAE) is a mouse model for Multiple sclerosis (MS). MS is an autoimmune disease can cause demyelination and axonal damage. In this study, our aim was to evaluate the therapeutic effect of G2013 as a new non-steroidal anti-inflammatory agent in EAE. Method: We performed EAE induction in female C57BL/6 mice (aged 10 weeks) by myelin oligodendrocyte glycoprotein 35–55 in Complete Freund’s Adjuvant emulsion, and used intraperitoneal injection of G2013 for the treatment of EAE. In this experiment, clinical evaluation was assessed. On day 21 post-immunization blood samples were taken from the heart for evaluation of total antioxidant, TNF-a, NO. The mice were sacrificed and brains and cerebellums were removed for histological analysis. Result: G2013 had beneficial effects on EAE by lower incidence, reduction in the severity, and a delay in the onset of disease. Histological analysis showed that inflammation criteria including the number of inflammatory cells and plaques as well as demyelination in G2013 treated mice were lower than control group. The serum level of NO in G2013-treated mice was significantly less than control animals. Conclusion: These data indicate that treatment with G2013 can reduce the disease progression in EAE.